The Guettler Lab

ADP-ribosyltransferases, an update on function and nomenclature.

Lüscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, Cohen M, Corda D, Dantzer F, Daugherty MD, Dawson TM, Dawson VL, Deindl S, Fehr AR, Feijs KLH, Filippov DV, Gagné JP, Grimaldi G, Guettler S, Hoch NC, Hottiger MO, Korn P, Kraus WL, Ladurner A, Lehtiö L, Leung AKL, Lord CJ, Mangerich A, Matic I, Matthews J, Moldovan GL, Moss J, Natoli G, Nielsen ML, Niepel M, Nolte F, Pascal J, Paschal BM, Pawłowski K, Poirier GG, Smith S, Timinszky G, Wang ZQ, Yélamos J, Yu X, Zaja R, Ziegler M

The FEBS Journal, 2021

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M

Journal for Immunotherapy of Cancer, 2019, 7 (1), 101

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M

Cancer Cell, 2019, 36 (1), 35-50.e9

Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase.

Pollock K, Liu M, Zaleska M, Meniconi M, Pfuhl M, Collins I, Guettler S

Scientific Reports, 2019, 9 (1), 19130

Solution NMR assignment of the ARC4 domain of human tankyrase 2.

Zaleska M, Pollock K, Collins I, Guettler S, Pfuhl M

Biomolecular NMR Assignments, 2019

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ

Nature Communications, 2018, 9 (1), 1849

Structural Basis for Auto-Inhibition of the NDR1 Kinase Domain by an Atypically Long Activation Segment.

Xiong S, Lorenzen K, Couzens AL, Templeton CM, Rajendran D, Mao DYL, Juang YC, Chiovitti D, Kurinov I, Guettler S, Gingras AC, Sicheri F

Structure (London, England : 1993), 2018, 26 (8), 1101-1115.e6

MOB1 Mediated Phospho-recognition in the Core Mammalian Hippo Pathway.

Couzens AL, Xiong S, Knight JDR, Mao DY, Guettler S, Picaud S, Kurinov I, Filippakopoulos P, Sicheri F, Gingras AC

Molecular & Cellular Proteomics : MCP, 2017, 16 (6), 1098-1110

Regulation of Protein Interactions by Mps One Binder (MOB1) Phosphorylation.

Xiong S, Couzens AL, Kean MJ, Mao DY, Guettler S, Kurinov I, Gingras AC, Sicheri F

Molecular & Cellular Proteomics : MCP, 2017, 16 (6), 1111-1125

Identifying and Validating Tankyrase Binders and Substrates: A Candidate Approach.

Pollock K, Ranes M, Collins I, Guettler S

Methods in Molecular Biology (Clifton, N.J.), 2017, 1608, 445-473